Andere talen Reviva Pharmaceuticals Holdings, Inc.

Aandelen

RVPH

US76152G1004

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,06 ^USD	-0,97%		-4,38%	-40,58%

15/04	Reviva Pharmaceuticals Holdings, Inc. krijgt toestemming van de U.S. Food and Drug Administration voor het registratie Fase 3 programma voor brilaroxazine bij schizofrenie	CI
15/04	Reviva Pharmaceuticals Holdings, Inc. rapporteert resultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia	15/04
Reviva Pharmaceuticals Holdings, Inc. Gains Alignment with U.S. Food and Drug Administration on its Registrational Phase 3 Program for Brilaroxazine in Schizophrenia	15/04
Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights	15/04
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting	26/03
Reviva to Present at the UBS Virtual CNS Day	11/03
Reviva to Present at the 36th Annual ROTH Conference	07/03
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference	20/02
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia	06/02
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference	25/01
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones	04/01
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum	11/12
Reviva Pharmaceuticals to Participate in The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference	30/11
Reviva Pharmaceuticals Closes $30 Million Registered Direct Offering	20/11
Reviva Pharmaceuticals Holdings, Inc. announced that it has received $2.999942 million in funding	20/11
Sector Update: Health Care Stocks Slightly Advancing Late Afternoon	16/11
Sector Update: Health Care Stocks Rise in Thursday Afternoon Trading	16/11
Sector Update: Health Care	16/11
Reviva Pharmaceuticals Launching $30 Million Registered Direct Offering; Shares Fall	16/11
Reviva Pharmaceuticals to Seek Acquisitions	16/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Reviva Pharmaceuticals Holdings, Inc.

Aandelen

RVPH

US76152G1004

Andere talen

Filters